Original Article

Predictive Factors for Septic Shock in Patients with Ventilator-Associated Pneumonia

Authors: Muge Aydogdu, MD, Gul Gursel, MD

Abstract


Background: Ventilator-associated pneumonia (VAP) is one of the most frequent infections in intensive care units (ICUs), and nearly 50% of patients with VAP develop septic shock. Septic shock is an independent predictor for mortality in these patients.


Objective: To investigate the predictors for septic shock in VAP patients receiving appropriate antibiotic therapy.


Methods: Eighty-nine patients with microbiologically confirmed VAP who were receiving appropriate antibiotic therapy were included in the study. They were divided into two groups according to the existence of septic shock. Clinical, hematological, biochemical and microbiological characteristics were compared.


Results: Thirty-seven percent of the patients developed septic shock. Advanced age (OR 1.07, 95% CI 1.02–1.13, P = 0.009), lymphocytopenia (<1000/mm3) (OR 7.48, 95% CI 1.91–29, P = 0.004), high blood glucose levels >120 mg/dL (OR 4.75, 95% CI 1.38–16, P = 0.014), and increased clinical pulmonary infection scores (CPIS) (OR 1.64, 95% CI 1.16–2.33, P = 0.006) were identified as independent predictors for the development of septic shock.


Conclusion: Some clinical parameters such as lymphocytopenia, blood glucose >120 mg/dL, increasing age, and CPIS can predict septic shock during VAP, but large randomized controlled studies are needed to confirm these results.



This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546–1554.
 
2. Padkin A, Goldfrad C, Brady AR, et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 2003;31:2332–2338.
 
3. Finfer S, Bellomo R, Lipman J, et al. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004;30:589–596.
 
4. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303–1310.
 
5. Valles J, Mesalles E, Mariscal D, et al. A 7-year study of severe hospital-acquired pneumonia requiring ICU admission. Intensive Care Med 2003;29:1981–1988.
 
6. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.
 
7. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995;274:639–644.
 
8. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462–474.
 
9. Luna CM, Aruj P, Niederman MS, et al; Grupo Argentino de Estudio de la Neumonia Asociada al Respirador (GANAR) group. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 2006;27:158–164.
 
10. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003;31:676–682.
 
11. Dellinger RP, Carlet JM, Masur H, et al; Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858–873.
 
12. Van den Berghe G. Beyond diabetes: saving lives with insulin in the ICU. Int J Obes Relat Metab Disord 2002;26(suppl 3):S3–S8.
 
13. Girard TD, Opal SM, Ely EW. Severe Sepsis in the Elderly. Yearbook of Intensive Care and Emergency Medicine. Springer, Berlin, Heidelberg, 2005, part 9, pp 437–448.
 
14. Gogos CA, Lekkou A, Papageorgiou O, et al. Clinical prognostic markers in patients with severe sepsis: a prospective analysis of 139 consecutive cases. J Infect 2003;47:300–306.
 
15. Harbarth S, Garbino J, Pugin J, et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003;115:529–535.
 
16. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742–2751.
 
17. Grubeck-Loebenstein B, Wick G. The aging of the immune system. Adv Immunol 2002;80:243–284.
 
18. Fry TJ, Mackall CL. Current concepts of thymic aging. Springer Semin Immunopathol 2002;24:7–22.
 
19. Weksler ME, Goodhardt M, Szabo P. The effect of age on B cell development and humoral immunity. Springer Semin Immunopathol 2002;24:35–52.
 
20. Douek DC, Koup RA. Evidence for thymic function in the elderly. Vaccine 2000;18:1638–1641.
 
21. Felmet KA, Hall MW, Clark RS, et al. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol 2005;174:3765–3772.
 
22. Hotchkiss RS, Chang KC, Grayson MH, et al. Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis. Proc Natl Acad Sci USA 2003;100:6724–6729.
 
23. Micek ST, Ward S, Fraser VJ, et al. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004;125:1791–1799.
 
24. Muhlestein JB, Anderson JL, Horne BD, et al. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneus coronary intervention. Am Heart J 2003;146:351–358.
 
25. Bochicchio GV, Sung J, Joshi M, et al. Persistent hyperglycemia is predictive of outcome of critically ill trauma patients. J Trauma 2005;58:921–924.
 
26. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359–1367.
 
27. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449–461.
 
28. Grey NJ, Perdrizet GA. Reduction of nosocomial infections in the surgical intensive care unit by strict glycemic control. Endocr Pract 2004;10(suppl 2):46–52.
 
29. Adrie C, Azoulay E, Francais A, et al. Influence of gender on the outcome of severe sepsis: a reappraisal. Chest 2007;132:1786–93. Epub 2007 Sep. 21.